While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

Despite this funding boost, Moderna has indicated that it does not expect this to contribute to its revenue in the near term, as the associated expenses are anticipated to offset the financial inflow.

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near ...

If you can use AI to make custom vaccines and cures for cancer, that could be a tremendous value to society and Moderna's business. More important in the near term, Moderna announced today that it ...

Moderna gains HHS backing for developing mRNA-based pandemic influenza vaccines, advancing clinical studies for up to five subtypes. Get Pro-Level Earnings Insights Before the Market Moves Tuesday ...

Moderna's chief executive. He stressed however that the mRNA-1273.214 candidate – which combines the current SpikeVax booster with an Omicron-specific candidate – is the company's lead ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Moderna's partnership with Merck in personalized ... the development of their 10 most promising product candidates with near-term commercial potential. Beyond the oncology product candidates ...